Lodz

• A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes (SURPASS-CV … Ended
  2023-507846-96-00 5 2020-06-19 Type 2 Diabetes Mellitus
• An Open-Label, Multi-Center Extension Study to Characterize the Long-Term Safety and Efficacy of BMS-986165 in Subjects with Moderate-to-Sev … Ended
  2022-502361-15-00 5 2019-12-12 Moderate-to-Severe Plaque Psoriasis
• Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) with a History of Frequent Exace … Ended
  2022-503050-39-00 5 2019-11-12 Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) w
• A Phase 3b Study to Evaluate the Duration of Effect of Bimatoprost SR in Participants with Open-Angle Glaucoma or Ocular Hypertension Ended
  2022-502380-37-00 5 2019-08-02 Open-Angle Glaucoma
• Phase 3 study of SBRT ± pembrolizumab for participants with unresectable Stage I or II NSCLC Ended
  2022-500413-11-00 5 2019-06-17 Unresected Stage I or II Non-Small Cell Lung Cancer (NSCLC)
• Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke Ended
  2023-503673-38-00 5 2019-05-24 Adults at high risk of cardiovascular events without prior MI or strok
• A Study of Baricitinib (LY3009104) in Children and Adolescents With Atopic Dermatitis (BREEZE-AD-PEDS) Ended
  2023-503898-38-00 5 2019-05-24 Atopic Dermatitis
• EASE SBS 2 (Evaluation of the efficacy and safety of Glepaglutide in the treatment of short bowel syndrome) (SBS) Ended
  2024-513374-22-00 5 2019-04-30 Short Bowel Syndrome
• Expanded access program for mepolizumab in subjects with hypereosinophilic syndrome. Ended
  2024-515247-28-00 5 2019-03-29 Hypereosinophilic Syndrome
• This is a phase III randomised, double-blind, placebo-controlled, multicentre, global study to assess the effectiveness and safety of standa … Ended
  2022-502747-35-00 5 2019-02-18 Newly diagnosed advanced (FIGO stage III-IV) high grade epithelial ova
• A Phase II trial find out the effectiveness and safety of durvalumab combined with olaparib compared to durvalumab alone, in treating patien … Ended
  2024-512769-16-00 4 2018-11-14 Stage IV Non Small Cell Lung Cancer whose tumors lack EGFR mutations a
• Effectiveness and Safety of Sparsentan as treatment for Primary Focal Segmental Glomerulosclerosis (FSGS) Ended
  2023-505494-32-00 5 2018-10-15 Focal segmental glomerulosclerosis (FSGS)
• A study that allows patients from previous studies to continue on the medication. The aim of the study is to determine how safe and effectiv … Ended
  2023-508955-37-00 5 2018-10-10 Moderate to severe atopic dermatitis
• Multicenter Extension Study of Oral Ozanimod in patients with Moderately to Severely Active Crohn's Disease Ended
  2024-511553-22-00 5 2018-10-05 Moderately to Severely Active Crohn's Disease
• Combinations of Cemiplimab (Anti-PD-1 Antibody) and Platinum-based Doublet Chemotherapy in Patients With Lung Cancer Ended
  2024-515051-38-00 5 2018-07-20 Non-small Cell Lung Cancer
• A Study to Evaluate the Efficacy and Safety of Polatuzumab Vedotin in Combination with Rituximab and CHP (R-CHP) Versus Rituximab and CHOP ( … Ended
  2024-516904-40-00 5 2018-03-27 Previously Untreated Diffuse large B-cell lymphoma (DLBCL)
• An extension study to investigate how safe Vedolizumab is in child patients with Ulcerative Colitis or Crohn's Disease Ended
  2023-507766-35-00 4 2018-01-09 Ulcerative Colitis or Crohn's Disease
• Study of REGN 2810 Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) Ended
  2024-515052-20-00 5 2017-09-20 Non-small Cell Lung Cancer
• A Study to Evaluate the Long-Term Efficacy, Safety, and Tolerability of Repeated Administration of Upadacitinib (ABT-494) in Participants Wi … Ended
  2024-510727-19-00 4 2016-10-11 Crohn's Disease (CD)
• A study of Iclusig (ponatinib), an oral kinase-inhibitor treatment administered, by standard dose or reduced doses, for patients with Philad … Ended
  2024-514516-27-00 4 2015-12-01 Chronic Phase Chronic Myeloid Leukemia
• A Multi-Center, Open-Label Study of Adalimumab to Evaluate Long-Term Safety and Tolerability of Repeated Administration of Adalimumab in Ped … Ended
  2023-504711-32-00 5 2015-11-24 Ulcerative Colitis
• A Study to Compare the Efficacy and Safety of a Combined Regimen of Obinutuzumab and Venetoclax (GDC-0199/ABT-199) Versus Obinutuzumab and … Ended
  2023-504034-22-00 5 2014-12-18 Chronic Lymphocytic Leukemia (CLL)
• A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight With Weight Related Comorbidities (SURMOUNT-5) Ended
  2022-501106-35-00 5 Obesity Overweight
• A trial to learn if andexanet alfa is safe and works to limit bleeding in people who take factor 10a inhibitors and urgently need surgery Ended
  2022-501353-37-00 5 Reversal of anticoagulation effect in patients on a FXa inhibitor (api

Showing 865–888 of 898 trials